Zai Lab

About:

Zai Lab brings transformative medicines for cancer, autoimmune, and infectious diseases to patients in China and around the world.

Website: https://zailaboratory.com

Twitter/X: ZaiLab_Global

Top Investors: Qiming Venture Partners, OrbiMed, HongShan, Kleiner Perkins, Cormorant Asset Management

Description:

Zai Lab is an innovative biopharmaceutical company based in Shanghai focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. Since their founding in 2014, their experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates. They see theirselves as the trusted partner of choice for global biopharmaceutical companies seeking to access the Chinese market. Leveraging their team’s extensive global drug development expertise, combined with their demonstrated understanding of the pharmaceutical industry, the increasingly favorable clinical and regulatory environment in China and their in-house manufacturing capabilities, they plan to continue to secure relationships with global pharmaceutical companies to further expand their pipeline and foster innovation in China. Their team is passionate about bringing transformative new medicines to patients. Their vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing their partner’s and their own products in China and around the world. To that end, they have built manufacturing capabilities to support the clinical and commercial production of their drug candidates in China, and they expect to have further clinical production capabilities in the near future. Their team is planning to establish a specialized commercial team to support marketing of their products in China and beyond, and they are expanding their discovery efforts both internally and through collaborations with leading academic institutions.